COMPANY OVERVIEW

Immuno-oncology company developing CAR T-Cell Therapy for treatment of Cancer.

---

LOCATION

Germantown, MD, USA

---

THERAPEUTIC AREAS

Oncology

---

WEBSITE

https://www.encartatx.com

---

CAREER WEBSITE

None

---

SOCIAL MEDIA

---

INVESTORS

---

---

PRESS RELEASES

Nov 4, 2021

Arcellx to Present New Clinical Data from its CART-ddBCMA Phase 1 Trial in Patients with Relapsed and Refractory Multiple Myeloma at the 63rd ASH Annual Meeting and Exposition

May 19, 2021

Arcellx to Present Data from Phase 1 Study of CART-ddBCMA Demonstrating Continued Positive Response in Patients with Relapsed and Refractory Multiple Myeloma at the 2021 ASCO Annual Meeting

May 13, 2021

Preclinical Data of Arcellx’s Novel Synthetic CAR-T Binding Domain Presented at the 2021 ASGCT Annual Meeting and the 2021 PEGS Summit

Apr 19, 2021

Arcellx Announces Executive Appointments

Apr 13, 2021

Arcellx Closes $115 Million Series C Financing to Advance its Pipeline of Adaptive and Controllable Cell Therapies

For More Press Releases

---